Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masami Takeuchi

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
Hemasphere|June 9, 2023
Prevalence and Clinical Outcome of Omicron Breakthrough Infection in Patients With Hematologic Disease: A Prospective Observational Cohort StudyKentaro Narita, Daisuke Ikeda, Mizuki Seki, et al.
Leukemia & Lymphoma|December 7, 2020
Development of <i>BCR-ABL1</i>-positive ɤδ T-cell leukemia after treatment for thymoma type B1Toshiki Terao, Hiroya Ashimine, Naoko Tsuyama, et al.
Scientific Reports|December 15, 2021
Association of loss of spleen visualization on whole-body diffusion-weighted imaging with prognosis and tumor burden in patients with multiple myelomaToshiki Terao, Youichi Machida, Ukihide Tateishi, et al.
British Journal of Haematology|February 16, 2022
Depletion of CD38-positive regulatory T cells by anti-CD38 monoclonal antibodies induces a durable response to SARS-CoV-2 vaccination in patients with plasma cell dyscrasiaToshiki Terao, Takashi Naduka, Daisuke Ikeda, et al.
Frontiers in Oncology|March 30, 2026
Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapyMitsuaki Oura, Masanori Toho, Daisuke Ikeda, et al.
Leukemia & Lymphoma|October 8, 2025
Soluble BCMA as a biomarker reflecting tumor volume and treatment response in Waldenström macroglobulinemiaMitsuaki Oura, Daisuke Ikeda, Shuichi Aikawa, et al.
British Journal of Haematology|November 8, 2022
Antibody status following booster vaccination against SARS-CoV-2 virus in patients with haematologic malignanciesDaisuke Ikeda, Toshiki Terao, Ami Fukumoto, et al.
Haematologica|December 19, 2025
Impact of the plasma cell quantification method on the International Myeloma Working Group diagnostic criteria for MGUS/SMMAtsushi Uehara, Hajime Sakuma, Fuminari Fujii, et al.
Comprehensive Reviews in Food Science and Food Safety|April 15, 2026
Rethinking Group B Streptococcus: The Rise of Sequence Type 283 as a Foodborne Zoonotic PathogenAbdulrakib Abdulrahim, Ruth N Zadoks, Timothy Barkham, et al.
British Journal of Haematology|May 25, 2026
Treatment-specific differences in soluble B-cell maturation antigen levels at minimum residual disease negativity in multiple myelomaMasanori Toho, Rikako Tabata, Kosuke Shima, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
Hemasphere|June 9, 2023
Prevalence and Clinical Outcome of Omicron Breakthrough Infection in Patients With Hematologic Disease: A Prospective Observational Cohort StudyKentaro Narita, Daisuke Ikeda, Mizuki Seki, et al.
Leukemia & Lymphoma|December 7, 2020
Development of <i>BCR-ABL1</i>-positive ɤδ T-cell leukemia after treatment for thymoma type B1Toshiki Terao, Hiroya Ashimine, Naoko Tsuyama, et al.
Scientific Reports|December 15, 2021
Association of loss of spleen visualization on whole-body diffusion-weighted imaging with prognosis and tumor burden in patients with multiple myelomaToshiki Terao, Youichi Machida, Ukihide Tateishi, et al.
British Journal of Haematology|February 16, 2022
Depletion of CD38-positive regulatory T cells by anti-CD38 monoclonal antibodies induces a durable response to SARS-CoV-2 vaccination in patients with plasma cell dyscrasiaToshiki Terao, Takashi Naduka, Daisuke Ikeda, et al.
Frontiers in Oncology|March 30, 2026
Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapyMitsuaki Oura, Masanori Toho, Daisuke Ikeda, et al.
Leukemia & Lymphoma|October 8, 2025
Soluble BCMA as a biomarker reflecting tumor volume and treatment response in Waldenström macroglobulinemiaMitsuaki Oura, Daisuke Ikeda, Shuichi Aikawa, et al.
British Journal of Haematology|November 8, 2022
Antibody status following booster vaccination against SARS-CoV-2 virus in patients with haematologic malignanciesDaisuke Ikeda, Toshiki Terao, Ami Fukumoto, et al.
Haematologica|December 19, 2025
Impact of the plasma cell quantification method on the International Myeloma Working Group diagnostic criteria for MGUS/SMMAtsushi Uehara, Hajime Sakuma, Fuminari Fujii, et al.
Comprehensive Reviews in Food Science and Food Safety|April 15, 2026
Rethinking Group B Streptococcus: The Rise of Sequence Type 283 as a Foodborne Zoonotic PathogenAbdulrakib Abdulrahim, Ruth N Zadoks, Timothy Barkham, et al.
British Journal of Haematology|May 25, 2026
Treatment-specific differences in soluble B-cell maturation antigen levels at minimum residual disease negativity in multiple myelomaMasanori Toho, Rikako Tabata, Kosuke Shima, et al.
Pageof 12